JP2017002041A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017002041A5 JP2017002041A5 JP2016114709A JP2016114709A JP2017002041A5 JP 2017002041 A5 JP2017002041 A5 JP 2017002041A5 JP 2016114709 A JP2016114709 A JP 2016114709A JP 2016114709 A JP2016114709 A JP 2016114709A JP 2017002041 A5 JP2017002041 A5 JP 2017002041A5
- Authority
- JP
- Japan
- Prior art keywords
- igg antibody
- recombinant igg
- composition
- antibody
- sialylated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 18
- 238000000034 method Methods 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 4
- 238000001042 affinity chromatography Methods 0.000 claims 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 3
- 102000003838 Sialyltransferases Human genes 0.000 claims 2
- 108090000141 Sialyltransferases Proteins 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 2
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- 238000004255 ion exchange chromatography Methods 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 238000010172 mouse model Methods 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78938406P | 2006-04-05 | 2006-04-05 | |
| US60/789,384 | 2006-04-05 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009504279A Division JP6084761B2 (ja) | 2006-04-05 | 2007-04-03 | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018053298A Division JP6686058B2 (ja) | 2006-04-05 | 2018-03-20 | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017002041A JP2017002041A (ja) | 2017-01-05 |
| JP2017002041A5 true JP2017002041A5 (enExample) | 2017-06-15 |
| JP6322849B2 JP6322849B2 (ja) | 2018-05-16 |
Family
ID=38581601
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009504279A Active JP6084761B2 (ja) | 2006-04-05 | 2007-04-03 | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
| JP2014182741A Pending JP2015038086A (ja) | 2006-04-05 | 2014-09-08 | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
| JP2016114709A Active JP6322849B2 (ja) | 2006-04-05 | 2016-06-08 | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
| JP2018053298A Active JP6686058B2 (ja) | 2006-04-05 | 2018-03-20 | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
| JP2020065891A Expired - Fee Related JP6989979B2 (ja) | 2006-04-05 | 2020-04-01 | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
| JP2021192123A Active JP7357382B2 (ja) | 2006-04-05 | 2021-11-26 | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009504279A Active JP6084761B2 (ja) | 2006-04-05 | 2007-04-03 | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
| JP2014182741A Pending JP2015038086A (ja) | 2006-04-05 | 2014-09-08 | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018053298A Active JP6686058B2 (ja) | 2006-04-05 | 2018-03-20 | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
| JP2020065891A Expired - Fee Related JP6989979B2 (ja) | 2006-04-05 | 2020-04-01 | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
| JP2021192123A Active JP7357382B2 (ja) | 2006-04-05 | 2021-11-26 | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (14) | US10167332B2 (enExample) |
| EP (3) | EP2815768A3 (enExample) |
| JP (6) | JP6084761B2 (enExample) |
| CN (1) | CN101432301B (enExample) |
| AU (1) | AU2007235413B2 (enExample) |
| CA (1) | CA2647524C (enExample) |
| EA (1) | EA022780B1 (enExample) |
| IL (1) | IL194526A (enExample) |
| MX (1) | MX2008012843A (enExample) |
| NZ (1) | NZ572379A (enExample) |
| WO (1) | WO2007117505A2 (enExample) |
| ZA (1) | ZA200808900B (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8470318B2 (en) | 2005-11-07 | 2013-06-25 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| US20080206246A1 (en) * | 2006-04-05 | 2008-08-28 | Ravetch Jeffrey V | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| JP6084761B2 (ja) * | 2006-04-05 | 2017-02-22 | ザ ロックフェラー ユニバーシティー | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
| AU2008282218A1 (en) | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
| US20110033378A1 (en) | 2008-01-18 | 2011-02-10 | Medlmmune, Llc. | Cysteine Engineered Antibodies For Site-Specific Conjugation |
| MX2010011598A (es) | 2008-04-22 | 2010-12-15 | Univ Rockefeller | Metodos para identificar compuestos anti-inflamatorios. |
| EP2233499A1 (en) | 2009-03-26 | 2010-09-29 | CSL Behring AG | Antibody composition with altered Fab sialylation |
| EP2233502A1 (en) | 2009-03-27 | 2010-09-29 | Deutsches Rheuma-Forschungszentrum Berlin | Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them |
| JP5918129B2 (ja) | 2009-06-22 | 2016-05-18 | メディミューン，エルエルシー | 部位特異的共役のための操作されたＦｃ領域 |
| AU2011249832A1 (en) | 2010-05-07 | 2012-12-20 | Csl Behring Ag | Antibody composition obtained by fractionation of plasma immunoglobulins affinity chromatography on a Sambucus nigra affinity column |
| RU2604811C2 (ru) | 2010-05-27 | 2016-12-10 | Мерк Шарп Энд Домэ Корп. | Способ получения антител с улучшенными свойствами |
| AR085302A1 (es) | 2011-02-24 | 2013-09-18 | Sanofi Sa | Metodo de produccion de anticuerpos sialilados |
| US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| SG11201403311SA (en) | 2011-12-19 | 2014-07-30 | Univ Rockefeller | Non-sialylated anti-inflammatory polypeptides |
| US12384848B2 (en) | 2011-12-19 | 2025-08-12 | The Rockefeller University | Anti-inflammatory polypeptides |
| CA3111357A1 (en) | 2011-12-23 | 2013-06-27 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| CA2905010A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| EP2855533A4 (en) | 2013-03-15 | 2015-11-25 | Momenta Pharmaceuticals Inc | METHODS RELATING TO CTLA4-FC FUSION PROTEINS |
| US11084871B2 (en) | 2013-04-18 | 2021-08-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Composition with reduced immunogenicity |
| EP2991666B1 (en) * | 2013-05-02 | 2020-03-25 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
| WO2014186310A1 (en) | 2013-05-13 | 2014-11-20 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
| EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| WO2015057622A1 (en) | 2013-10-16 | 2015-04-23 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| WO2015186004A2 (en) * | 2014-06-02 | 2015-12-10 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Production of fc fragments |
| AU2015332634B2 (en) | 2014-10-15 | 2020-05-14 | Xenothera | Composition with reduced immunogenicity |
| CN107847586A (zh) | 2015-03-04 | 2018-03-27 | 洛克菲勒大学 | 抗炎多肽 |
| FR3038517B1 (fr) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| KR102878970B1 (ko) | 2016-08-03 | 2025-10-30 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항-SIRPalpha 항체 요법의 대식세포 증진 효능에서 Fc 수용체 참여의 붕괴 |
| SI4050034T1 (sl) | 2016-09-14 | 2024-07-31 | Teneoone, Inc. | Protitelesa, ki se vežejo na CD3 |
| BR112019012354A2 (pt) | 2016-12-21 | 2019-11-26 | Teneobio Inc | anticorpos apenas de cadeia pesada anti-bcma |
| CN111448210B (zh) | 2017-07-26 | 2024-05-14 | 四十七公司 | 抗SIRP-α抗体及相关方法 |
| CA3075399A1 (en) | 2017-09-13 | 2019-03-21 | Teneobio, Inc. | Heavy chain antibodies binding to ectoenzymes |
| BR112020012308A2 (pt) | 2017-12-19 | 2020-11-24 | The Rockefeller University | variantes domínios de igg fc humanos com função de efeito melhorada |
| KR20250034193A (ko) | 2017-12-27 | 2025-03-10 | 테네오바이오, 인코포레이티드 | Cd3-델타/엡실론 이형이량체 특이적 항체 |
| KR102579246B1 (ko) | 2018-07-03 | 2023-09-19 | 길리애드 사이언시즈, 인코포레이티드 | HIV gp120을 표적화하는 항체 및 사용 방법 |
| US20210347848A1 (en) | 2018-08-31 | 2021-11-11 | ALX Oncology Inc. | Decoy polypeptides |
| JP2022501357A (ja) | 2018-09-21 | 2022-01-06 | テネオバイオ， インコーポレイテッド | ヘテロ二量体多重特異性抗体を精製するための方法 |
| EP3863673A4 (en) * | 2018-10-11 | 2023-01-11 | Momenta Pharmaceuticals, Inc. | TREATMENT WITH HIGHLY SIALYLATED IGG COMPOSITIONS |
| BR112021000173A2 (pt) | 2018-10-26 | 2021-05-04 | Teneobio, Inc. | anticorpos de cadeia pesada com ligação a cd38 |
| CN110297093B (zh) * | 2019-03-18 | 2022-04-22 | 山西瑞豪生物科技有限公司 | 一种检测人免疫球蛋白g4的方法和试剂盒 |
| KR102549282B1 (ko) * | 2019-11-18 | 2023-06-30 | 건국대학교 산학협력단 | 시알산화된 면역글로불린을 유효성분으로 포함하는 염증성 질환의 치료용 조성물 |
| US20220372162A1 (en) | 2019-12-18 | 2022-11-24 | TeneoFour, Inc. | Pct/us2020/066088 |
| WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
| JP2025542423A (ja) * | 2022-12-21 | 2025-12-25 | コングク ユニバーシティ インダストリアル コーオペレーション コーポレーション | α－２，６－シアル化免疫グロブリンの眼球乾燥症または炎症性眼疾患の予防または治療用途 |
| CN115819560A (zh) * | 2022-12-27 | 2023-03-21 | 河南赛诺特生物技术有限公司 | 制备第二抗体的方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| FR2556219B1 (fr) * | 1983-12-07 | 1987-06-26 | Merieux Inst | Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5047335A (en) * | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
| US5401650A (en) * | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| CZ96893A3 (en) * | 1990-11-23 | 1993-12-15 | Gen Hospital Corp | Inhibition of adhesive protein cells and their carbohydrates interaction |
| US5453272A (en) | 1992-10-02 | 1995-09-26 | Alberta Research Council | Lectin derived carbohydrate binding-peptide |
| MX9603773A (es) * | 1994-03-03 | 1997-07-31 | Genentech Inc | Anticuerpos monoclonales anti-interleucina-8 para el tratamiento de trastornos inflamatorios. |
| US5705364A (en) * | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
| US6656466B1 (en) | 1995-06-06 | 2003-12-02 | Genetech, Inc. | Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition |
| US20020045207A1 (en) | 1997-10-31 | 2002-04-18 | Lynne A. Krummen | Glycoprotein production process |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| ATE536417T1 (de) * | 1999-04-15 | 2011-12-15 | Crucell Holland Bv | Herstellung von rekombinanten proteinen in einer menschlichen zelle mit mindestens einem e1 adenovirus protein |
| US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
| DE19927835A1 (de) * | 1999-06-18 | 2000-12-21 | Clariant Gmbh | Verwendung von verbesserten Cyanpigmenten in elektrophotographischen Tonern und Entwicklern, Pulverlacken und Ink-Jet-Tinten |
| US7064191B2 (en) * | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| JPWO2002030954A1 (ja) * | 2000-10-06 | 2004-02-19 | 協和醗酵工業株式会社 | 抗体を精製する方法 |
| WO2002040047A2 (en) | 2000-11-20 | 2002-05-23 | Canadian Blood Services | Method for treating thrombocytopenia with monoclonal ivig |
| US7473680B2 (en) | 2001-11-28 | 2009-01-06 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
| US7427469B2 (en) * | 2002-11-05 | 2008-09-23 | Institut Pasteur | Method of treating cytomegalovirus with DC-SIGN blockers |
| CN100402660C (zh) * | 2002-12-23 | 2008-07-16 | 布里斯托尔-迈尔斯斯奎布公司 | 用于蛋白质生产的哺乳动物细胞培养方法中产物质量提高 |
| US20070048740A1 (en) * | 2003-02-14 | 2007-03-01 | Research Association For Biotechnology | Full-length cDNA |
| NZ587776A (en) * | 2003-04-09 | 2012-03-30 | Genentech Inc | Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor using anti-CD20 antibody |
| JP2007528195A (ja) | 2003-10-09 | 2007-10-11 | デウン カンパニー，リミテッド | 高シアル酸含量のヒトトロンボポエチンを精製する方法 |
| ME01775B (me) * | 2003-11-05 | 2011-02-28 | Glycart Biotechnology Ag | Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
| JP2008504222A (ja) * | 2003-12-15 | 2008-02-14 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 新規の抗ｄｃ−ｓｉｇｎ抗体 |
| BRPI0417916A (pt) * | 2003-12-31 | 2007-04-10 | Merck Patent Gmbh | proteìna de fusão de fc-eritropoietina com farmacocinética melhorada |
| ES2543685T3 (es) * | 2005-06-30 | 2015-08-21 | Janssen Biotech, Inc. | Métodos y composiciones con actividad terapéutica mejorada |
| CN102628074B (zh) * | 2005-08-19 | 2015-07-29 | 詹森生物科技公司 | 抗蛋白酶解的抗体制剂 |
| US8470318B2 (en) * | 2005-11-07 | 2013-06-25 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| WO2007055916A2 (en) | 2005-11-07 | 2007-05-18 | The Rockefeller University | Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof |
| US20080206246A1 (en) * | 2006-04-05 | 2008-08-28 | Ravetch Jeffrey V | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| WO2008057634A2 (en) | 2006-10-26 | 2008-05-15 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| JP6084761B2 (ja) | 2006-04-05 | 2017-02-22 | ザ ロックフェラー ユニバーシティー | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
| ES2587742T3 (es) | 2007-12-27 | 2016-10-26 | Baxalta GmbH | Métodos para diferenciar en una muestra proteína derivada de plasma de proteína recombinante |
-
2007
- 2007-04-03 JP JP2009504279A patent/JP6084761B2/ja active Active
- 2007-04-03 EA EA200870411A patent/EA022780B1/ru unknown
- 2007-04-03 AU AU2007235413A patent/AU2007235413B2/en active Active
- 2007-04-03 MX MX2008012843A patent/MX2008012843A/es active IP Right Grant
- 2007-04-03 EP EP14183260.0A patent/EP2815768A3/en not_active Ceased
- 2007-04-03 CN CN200780015563.6A patent/CN101432301B/zh active Active
- 2007-04-03 CA CA2647524A patent/CA2647524C/en active Active
- 2007-04-03 NZ NZ572379A patent/NZ572379A/en not_active IP Right Cessation
- 2007-04-03 EP EP07754846.9A patent/EP2010566B2/en active Active
- 2007-04-03 EP EP18188349.7A patent/EP3456351A1/en not_active Withdrawn
- 2007-04-03 US US12/294,883 patent/US10167332B2/en active Active
- 2007-04-03 WO PCT/US2007/008396 patent/WO2007117505A2/en not_active Ceased
-
2008
- 2008-10-05 IL IL194526A patent/IL194526A/en active IP Right Grant
- 2008-10-17 ZA ZA200808900A patent/ZA200808900B/xx unknown
-
2013
- 2013-05-16 US US13/896,070 patent/US20130273040A1/en not_active Abandoned
-
2014
- 2014-05-16 US US14/280,181 patent/US20140323696A1/en not_active Abandoned
- 2014-09-08 JP JP2014182741A patent/JP2015038086A/ja active Pending
-
2015
- 2015-02-17 US US14/624,483 patent/US20160176950A1/en not_active Abandoned
-
2016
- 2016-06-08 JP JP2016114709A patent/JP6322849B2/ja active Active
- 2016-10-07 US US15/288,764 patent/US20170088608A1/en not_active Abandoned
-
2017
- 2017-04-20 US US15/492,987 patent/US20170218050A1/en not_active Abandoned
- 2017-06-21 US US15/629,119 patent/US20170320935A1/en not_active Abandoned
- 2017-06-21 US US15/629,056 patent/US20170283492A1/en not_active Abandoned
-
2018
- 2018-03-20 JP JP2018053298A patent/JP6686058B2/ja active Active
- 2018-09-28 US US16/145,688 patent/US20190031737A1/en not_active Abandoned
- 2018-10-02 US US16/150,058 patent/US20190031738A1/en not_active Abandoned
-
2019
- 2019-01-10 US US16/245,053 patent/US20190127446A1/en not_active Abandoned
- 2019-12-20 US US16/724,137 patent/US20200385443A1/en not_active Abandoned
-
2020
- 2020-04-01 JP JP2020065891A patent/JP6989979B2/ja not_active Expired - Fee Related
- 2020-12-14 US US17/121,622 patent/US20210101961A1/en not_active Abandoned
-
2021
- 2021-11-26 JP JP2021192123A patent/JP7357382B2/ja active Active
-
2022
- 2022-12-20 US US18/085,190 patent/US20230121427A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017002041A5 (enExample) | ||
| FI3736291T3 (fi) | Anti-fcrh5-vasta-aineita | |
| HRP20250807T1 (hr) | Protutijela koja vežu ljudski cgrp receptor | |
| WO2014160463A8 (en) | Prefusion rsv f proteins and their use | |
| JP2011173914A5 (enExample) | ||
| JP2016027050A5 (enExample) | ||
| JP2014508759A5 (enExample) | ||
| HRP20231579T1 (hr) | Anti-ctla-4 antitijela i postupci njihove upotrebe | |
| JP2014077000A5 (enExample) | ||
| JP2015533795A5 (enExample) | ||
| HRP20240182T1 (hr) | Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2) | |
| JP2015522252A5 (enExample) | ||
| RU2010120879A (ru) | Антитела против g-белка распираторно-синцитиального вируса (rsv) | |
| IL259940B2 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| HRP20201345T1 (hr) | Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba | |
| HRP20130204T1 (hr) | Monoklonalna protutijela koja se vežu na hgm-csf i medicinski sastavi koji ih sadrže | |
| JP2010504361A (ja) | 安定した抗体製剤およびその使用 | |
| HRP20192052T1 (hr) | Protutijela anti-siglec-8 te njihovi postupci i uporabe | |
| HRP20170815T1 (hr) | Agonisti receptora 1 fibroblastnog čimbenika rasta i postupci uporabe | |
| BR112015022288A2 (pt) | 2-aminopirimidin-6-onas e análogos exibindo atividades anticâncer e antiproliferativas, sua composição faramcêutica e seus usos | |
| JP2011137002A (ja) | 組換えｉｌ−９抗体およびその使用 | |
| JP2017536102A5 (enExample) | ||
| HRP20200767T1 (hr) | Humanizirana anti-humana cd19 protutijela i postupci uporabe | |
| RU2013143358A (ru) | Анти-fgfr4 антитела и способы их применения | |
| JP2016503413A5 (enExample) |